NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss

F. Janku, O. Jegede, S. L. Puhalla, P. Konstantinopoulos, F. Meric-Bernstam, E. P. Mitchell, J. A. Zwiebel, L. M. McShane, S. Li, L. V. Rubinstein, L. A. Doyle, D. Patton, B. A. Conley, P. J. O'Dwyer, L. N. Harris, C. Arteaga, P. M. Williams, S. R. Hamilton, A. P. Chen, K. T. Flaherty

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)viii137
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Janku, F., Jegede, O., Puhalla, S. L., Konstantinopoulos, P., Meric-Bernstam, F., Mitchell, E. P., Zwiebel, J. A., McShane, L. M., Li, S., Rubinstein, L. V., Doyle, L. A., Patton, D., Conley, B. A., O'Dwyer, P. J., Harris, L. N., Arteaga, C., Williams, P. M., Hamilton, S. R., Chen, A. P., & Flaherty, K. T. (2018). NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii137. https://doi.org/10.1093/annonc/mdy279.406